Updates In Esophageal & Gastric Cancers: When Dose Of Xeloda & Oxaliplatin Is Reduced In Frail Patients They Did Very Well & Had Less Toxicity
Nicholas Rohs MD @NickRohsMD Of Mount Sinai Discusses Updates In Esophageal & Gastric Cancers: When Dose Of Xeloda & Oxaliplatin Is Reduced In Frail Patients They Did Very Well & Had Less Toxicity.
Author: Annual-Meeting
Added: 06/04/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 4, 2019 Category: Cancer & Oncology Source Type: podcasts
Lower Doses Of Xeloda & Oxaliplatin: Physicians Would Be Happy To Give A Lower Dose If Data Supports
Nicholas Rohs MD @NickRohsMD Of Mount Sinai Discusses Lower Doses Of Xeloda & Oxaliplatin: Physicians Would Be Happy To Give A Lower Dose If Data Supports.
Author: Annual-Meeting
Added: 06/04/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 4, 2019 Category: Cancer & Oncology Source Type: podcasts
Pembrolizumab, Trastuzumab, Capecitabine & Oxaliplatin In HER2+ mEGA
David Ilson, MD, PhD Attending Physician, Memorial Sloan Kettering Cancer Center, Professor of Medicine, Weill Cornell Medical College, Discusses Pembrolizumab, Trastuzumab, Capecitabine & Oxaliplatin...
Author: obr
Added: 02/06/2019 (Source: Oncology Tube)
Source: Oncology Tube - February 6, 2019 Category: Cancer & Oncology Source Type: podcasts
The outcomes of the PRODIGY7 study in mCRC
Howard Hochster, MD, shares his perspective on the outcomes of the PRODIGY7 study in metastatic colorectal cancer patients using heated single agent oxaliplatin after surgery at the 2018 Annual Meetin...
Author: obr
Added: 07/24/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 24, 2018 Category: Cancer & Oncology Source Type: podcasts
Will Adjuvant Oxaliplatin Data Change Practice in CRC?
Dr John Marshall previews the GI cancer studies being presented at ASCO with his picks for the ones to watch, and predicts that a plenary presentation may be practice-changing. (Source: Medscape Oncology)
Source: Medscape Oncology - May 26, 2017 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts
Debate 5: Is There a Role for Adjuvant Oxaliplatin in Rectal Cancer? - Yes
Filmed on location in New York during the Great Debates and Updates in GI Malignancies 2015, this webcast is part of a series that provides educational discussions on controversial areas in the manage...
Author: imedex
Added: 09/06/2015 (Source: Oncology Tube)
Source: Oncology Tube - September 6, 2015 Category: Cancer & Oncology Source Type: podcasts
Debate 5: Is There a Role for Adjuvant Oxaliplatin in Rectal Cancer? - No
Filmed on location in New York during the Great Debates and Updates in GI Malignancies 2015, this webcast is part of a series that provides educational discussions on controversial areas in the manage...
Author: imedex
Added: 09/06/2015 (Source: Oncology Tube)
Source: Oncology Tube - September 6, 2015 Category: Cancer & Oncology Source Type: podcasts
Phase III CALGB/SWOG 80405 Trial
Results from the phase III CALGB/SWOG 80405 trial at the 2014 ASCO Annual Meeting. The CALGB/SWOG 80405 trial looked at irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) w...
Author: feeds
Added: 05/08/2015 (Source: Oncology Tube)
Source: Oncology Tube - May 8, 2015 Category: Cancer & Oncology Source Type: podcasts
No Adjuvant Oxaliplatin for Elderly CRC Patients
Consensus guidelines offer distinct recommendations for adjuvant and palliative treatments in elderly patients with colorectal cancer, as discussed by Dr David Kerr. (Source: Medscape Oncology)
Source: Medscape Oncology - April 15, 2015 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts
